This product is freeze dried. All water molecules have been removed.
Every lot is tried & tested in a relevant biological assay.
Cruz, L.J. et al. (1985) J. Biol. Chem. 260, 9280.
Alomone Labs μ-Conotoxin GIIIB inhibits NaV1.4 channels heterologously expressed in Xenopus oocytes.100 nM μ-Conotoxin GIIIB (#C-270) inhibited Na+ currents. Holding potential was -100 mV and test pulses of 25 ms to -20 mV were delivered every 5 sec. Left: Time course of current inhibition by toxin and recovery. The bar represents period of toxin perfusion. Right: Superimposed traces of NaV1.4 current before (black) and during (orange) application of μ-Conotoxin GIIIB.
µ-Conotoxin GIIIB was originally isolated from the marine snail Conus geographus and this is a synthetic version of the peptide. µ-Conotoxin GIIIB selectively blocks NaV1.4 channels, which are expressed predominantly in muscle.1,2 It is a potent blocker and 600 nM completely blocked NaV1.4-related currents in rat skeletal muscle.3
EDL muscle fibers from SBMA mice show reduced sensitivity to µ-Conotoxin GIIIB.Traces of action potentials before and after incubation in 2.5 µM µ-Conotoxin GIIIB (#C-270) for 30 minutes. Potentials were blocked in WT fibers (left) but not in diseased fibers (right).Adapted from Xu, Y. et al. (2016) J. Neurosci. 36, 5094. with permission of The Society for Neuroscience.
µ-Conotoxin GIIIB (#C-270) is a highly pure, synthetic, and biologically active peptide toxin.
- Bradford, A.B. et al. (2018) Toxicol. Appl. Pharmacol. 341, 77.
- Chand, K.K. et al. (2018) FASEB J. 32, 2676.
- Laghaei, R. et al. (2018) J. Neurophysiol. 119, 1340.
- Wang, X. et al. (2018) J. Neurosci. 38, 1725.
- Wu, M. et al. (2018) Neuropharmacology 131, 176.
- Bertone, N.I. et al. (2017) Synapse 71, e2209.
- Hurtado, E. et al. (2017) Front. Mol. Neurosci. 10, 147.
- Hurtado, E. et al. (2017) Front. Mol. Neurosci. 10, 270.
- Ng, F. et al. (2017) Muscle Nerve 55, 223.
- Zanetti, G. et al. (2017) PLoS Pathog. 13, e1006567.
- Bronnimann, D. et al. (2016) PLoS ONE 11, e0150948.
- Ouanounou, G. et al. (2016) eLife 5, e12190.
- Spaulding, E.L. et al. (2016) J. Neurosci. 36, 3254.
- Willadt, S. et al. (2016) Sci. Rep. 6, 24849.
- Xu, Y. et al. (2016) J. Neurosci. 36, 5094.
- Duregottia, E. et al. (2015) Proc. Natl. Acad. Sci. USA. 112, E497.
- Wu, Y.J. et al. (2015) J. Neurophysiol. 114, 2404.
- Ruiz, R. et al. (2014) Neuropharmacology 76, 106.
- Ackermann, B. et al. (2013) Hum. Mol. Genet. 22, 1328.
- Baskaran, P. et al. (2013) Toxicon 72, 71.
- Krieger, F. et al. (2013) Neurobiol. Dis. 54, 169.
- Rodrigues, H.A. et al. (2013) PLoS ONE 8, e78342.
- Tarr, T.B. et al. (2013) J. Neurosci. 33, 10559.
- µ-Conotoxin BuIIIC (#STC-690)
- µ-Conotoxin GIIIA (#STC-280)
- µ-Conotoxin SxIIIA (#STC-645)
- Anti-SCN4A (NaV1.4) Antibody (#ASC-020)
- Anthopleurin-C (#A-400)
- BmKI Toxin (#STB-100)
- QX-314 bromide (#Q-100)
- Tetrodotoxin citrate (#T-550)
- Veratridine (#V-110)
- TTX-Sensitive NaV Channel Antibody Explorer Kit (#AK-224)
- TTX-Sensitive NaV Channel Blocker Explorer Kit (#EK-105)
- NaV Channel Activator Explorer Kit (#EK-203)
- α-Bungarotoxin (#B-100)
- α-Bungarotoxin-ATTO-488 (#B-100-AG)
- α-Bungarotoxin-ATTO-633 (#B-100-FR)
- α-Bungarotoxin-Biotin (#B-100-B)
- α-Bungarotoxin-FITC (#B-100-F)